| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 4 securities · passive | ||||||
|
Lyell Immunopharma, Inc.
13G/A
LYEL · 55083R203
|
2.7% |
8/14/2026
Event 6/30/2026
|
||||
| Foresite Capital Fund IV, L.P. | 0% | |||||
| Foresite Capital Management IV, LLC | 0% | |||||
| Foresite Capital Fund V, L.P. | 1.9% | |||||
| Foresite Capital Management V, LLC | 1.9% | |||||
| Foresite Capital Opportunity Fund V, L.P. | 0.7% | |||||
| Foresite Capital Opportunity Management V, LLC | 0.7% | |||||
| James B. Tananbaum | 2.7% | |||||
|
Eikon Therapeutics, Inc.
13G
EIKN · 282564103
|
7.7% |
2/11/2026
Event 2/4/2026
|
||||
| Foresite Capital Fund IV, L.P. | 3.6% | |||||
| Foresite Capital Management IV, LLC | 3.6% | |||||
| Foresite Capital Fund V, L.P. | 2.5% | |||||
| Foresite Capital Management V, LLC | 2.5% | |||||
| Foresite Capital Opportunity Fund V, L.P. | 0.8% | |||||
| Foresite Capital Opportunity Management V, LLC | 0.8% | |||||
| Foresite Capital VI-A, LLC | 0.8% | |||||
| Foresite Capital VI-A Management, LLC | 0.8% | |||||
| James B. Tananbaum | 7.7% | |||||
|
Maze Therapeutics, Inc.
13G/A
MAZE · 578784100
|
1.4% |
11/14/2025
Event 9/30/2025
|
||||
| Foresite Capital Fund IV, L.P. | 1.2% | |||||
| Foresite Capital Management IV, LLC | 1.2% | |||||
| Foresite Capital Fund V, L.P. | 0.2% | |||||
| Foresite Capital Management V, LLC | 0.2% | |||||
| James Tananbaum | 1.4% | |||||
|
Lyell Immunopharma, Inc.
13G/A
LYEL · 55083R104
|
9.2% |
5/15/2025
Event 3/31/2025
|
||||
| Foresite Capital Fund IV, L.P. | 5.4% | |||||
| Foresite Capital Management IV, LLC | 5.4% | |||||
| Foresite Capital Fund V, L.P. | 2.8% | |||||
| Foresite Capital Management V, LLC | 2.8% | |||||
| Foresite Capital Opportunity Fund V, L.P. | 1.0% | |||||
| Foresite Capital Opportunity Management V, LLC | 1.0% | |||||
| James B. Tananbaum | 9.2% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.